Abstract
Background Hypersensitivity reactions to parenteral administered antibiotics (HRPA) are a substantial problem in managing pulmonary disease in Cystic Fibrosis (CF), especially in advanced CF. This group of patients requires a life long antibiotic treatment with extremely high cumulative doses compared to other patients. In our daily routine we observed a growing number of hypersensitivities. Therefore we conducted this observational study to assess HRPA s impact on the daily clinical work with CF, as well as it’s nature, frequency and predisposing risk factors.
Highlights
Hypersensitivity reactions to parenteral administered antibiotics (HRPA) are a substantial problem in managing pulmonary disease in Cystic Fibrosis (CF), especially in advanced CF
Our results demonstrate that HRPA with a prevalence of 60% are very relevant
During days 1-4 of antibiotic treatment courses patients might be at elevated risk to experience HRPA
Summary
Hypersensitivity reactions to parenteral administered antibiotics (HRPA) are a substantial problem in managing pulmonary disease in Cystic Fibrosis (CF), especially in advanced CF. This group of patients requires a life long antibiotic treatment with extremely high cumulative doses compared to other patients. In our daily routine we observed a growing number of hypersensitivities. We conducted this observational study to assess HRPAs impact on the daily clinical work with CF, as well as it’s nature, frequency and predisposing risk factors
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.